Steris Earnings Outlook

Steris Corporation (STE) is a leading provider of infection prevention products and services, with a market capitalization of $20.6 billion. The company is expected to report its fiscal first‑quarter earnings for 2027 soon, with analysts predicting a profit of $2.52 per share on a diluted basis, representing a 7.7% increase from the previous year's quarter. This marks the fourth consecutive quarter where STE has beaten or matched consensus estimates. For the full year, analysts expect STE to report EPS of $11.18 in fiscal 2026, a 9.9% increase from the previous year. This growth is expected to continue, with EPS projected to rise 7.7% year over year to $12.04 in fiscal 2028. Despite underperforming the S&P 500 Index and the State Street Health Care Select Sector SPDR ETF over the past 52 weeks, STE stock has a reasonably bullish consensus opinion from analysts, with a "Moderate Buy" rating overall. A strong majority of analysts, five out of eight, recommend a "Strong Buy" rating, while three advise a "Hold." The average analyst price target for STE is $254.43, indicating a potential upside of 15.1% from current levels.